NCT00441987已完成1 期
A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-953 Administered Orally to Healthy Japanese Male Subjects and Healthy Elderly Male Japanese Subjects.
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 96 人开始时间: 2007年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 96
- 主要终点
- Number of participants reporting Adverse Event
研究概览
简要总结
The purpose of the protocol is to assess the initial pharmacokinetic (PK) profile of a single oral dose of GSI-953 to healthy male Japanese subjects and healthy elderly male Japanese subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 20 Years 至 120 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Single Dose of GSI-953
Experimental
干预措施: GSI-953 (Drug)
结局指标
主要结局
Number of participants reporting Adverse Event
时间窗: 10 months
Safety
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Study Evaluating The SBI-087 In Subjects With Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT00714116Pfizer30
已完成
1 期
Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy AdultsHealthyNCT02860806Janssen-Cilag International NV66
已完成
1 期
Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With SchizophreniaSchizophreniaNCT06276361Rovi Pharmaceuticals Laboratories58
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male SubjectsHealthy VolunteersPharmacokinetics of ASP3700NCT02155504Astellas Pharma Europe B.V.44
已完成
1 期
Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese SubjectsAlzheimer DiseaseHealthyNCT00684710Wyeth is now a wholly owned subsidiary of Pfizer56